DOMH
Dominari Holdings Inc.
NASDAQ · Financial Services · Financial - Capital Markets · US
$2.10
−1.41%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.3x
Market Cap
$50.91M
MomentumView details →
1D Return
−1.41%
YTD Return
−57.37%
RSI (14)
30.9
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.3x
Market Cap
$50.91M
RSI (14)
30.9
MomentumView details →
1D Return
−1.41%
YTD Return
−57.37%
SummaryUpdated Jun 1, 2026
Dominari Holdings Inc. (NASDAQ:DOMH) is a biotechnology company founded in 1967 and headquartered in New York, New York. Originally incorporated as Aikido Pharma Inc., the company rebranded to its current name in December 2022. With a history spanning over five decades, Dominari has evolved from its early origins to focus on developing innovative small-molecule therapeutics for cancer treatment and antiviral applications. The company operates in the highly regulated and capital-intensive biotechnology sector, where drug development timelines typically span many years and require substantial investment before generating meaningful revenue.
Similar companies
Latest newsMore news →
Dominari Holdings Inc. signed Inducement Agreements offering holders of its outstanding Series A Warrants two options: exercise all warrants for cash at a reduced exercise price of $2.20 per share, or exchange all unexercised warrants for common stock at a 5:1 exchange ratio, with elections due by September 11, 2026, and expected gross proceeds of approximately $2.9 million from cash exercises.22d agoDominari Holdings Inc. announced its financial results for the quarter ended March 31, 2026, reporting a narrowed operating loss of $1.1 million compared to $14.9 million in the same quarter of 2025, and a 14% year-to-date revenue increase over 2025.24d ago